Welcome to our dedicated page for Biorestorative Therapies news (Ticker: BRTX), a resource for investors and traders seeking the latest updates and insights on Biorestorative Therapies stock.
BioRestorative Therapies develops regenerative medicine products using cell and tissue protocols, primarily involving adult stem cells. News about BRTX centers on BRTX-100, its autologous hypoxic-cultured mesenchymal stem cell therapy for chronic lumbar disc disease, including clinical trial updates, safety and efficacy data presentations, and regulatory interactions tied to the program.
The company also reports developments involving its ThermoStem metabolic program and its commercial BioCosmeceutical platform. Recurring updates include scientific conference presentations, collaborations supporting BioCosmeceutical commercialization, capital actions, shareholder communications, and business updates related to development spending and platform expansion.
BioRestorative Therapies (NASDAQ: BRTX) announced the closing of a public offering, raising approximately $23 million by issuing 2,300,000 units priced at $10.00 each. Each unit includes one share of common stock and a warrant to purchase an additional share at the same price, exercisable immediately for five years. The offering's proceeds will support BRTX's clinical programs in stem cell-based treatments for spinal and metabolic disorders. The company's stock was recently listed on the Nasdaq Capital Market.
BioRestorative Therapies, Inc. (NASDAQ: BRTX) has announced a public offering of 2,300,000 units, priced at $10.00 each, consisting of common stock and warrants. The offering is projected to raise gross proceeds of $23 million. This marks a significant milestone as the company's common stock will begin trading on The Nasdaq Capital Market under the ticker symbol 'BRTX' from November 5, 2021. The offering is expected to close around November 9, 2021, and includes an option for underwriters to purchase up to 345,000 additional shares. Funds raised aim to enhance the company’s financial position.
BioRestorative Therapies (BRTX) announced a 1-for-4,000 reverse stock split to facilitate its planned listing on The Nasdaq Capital Market. The split is effective from October 27, 2021, with the temporary ticker symbol BRTXD. Following the split, outstanding shares will decrease from approximately 3.49 billion to 872,211. The company believes this action meets Nasdaq's initial listing requirements, enhancing its appeal to institutional investors and access to capital.
BioRestorative Therapies, Inc. (OTC: BRTX) announced the nomination of Patrick F. Williams and David Rosa to its Board of Directors. This strategic move reflects the company's aim to enhance leadership with experienced professionals in the medical device industry. Williams, CFO at STAAR Surgical, and Rosa, CEO of NeuroOne, will bring valuable expertise to support BioRestorative's focus on cell therapies and overall growth. Their election is contingent upon the effectiveness of the company’s pending registration statement.
BioRestorative Therapies (OTC: BRTX) announced a significant milestone on September 23, 2021, as the Israeli Patent Office granted a Notice of Allowance for its ThermoStem program patent application. This patent will safeguard the use of implantable scaffolds that incorporate human brown adipose tissue stem cells, potentially treating various degenerative and metabolic disorders. CEO Lance Alstodt expressed satisfaction with the broader protection provided by this allowance compared to existing US patents, highlighting the technology's therapeutic relevance.
BioRestorative Therapies (OTC: BRTX) announced the issuance of a significant patent by the Australian Patent Office for its ThermoStem® Program. The patent covers an implantable scaffold using brown adipose-derived stem cells and methods of use to treat metabolic disorders. Initial preclinical research suggests that increased levels of brown fat can enhance caloric burning and reduce glucose and lipid levels, potentially lowering obesity and diabetes risks. The CEO emphasized the patent's importance for delivery methods in ongoing program development.
BioRestorative Therapies (OTC: BRTX) announced the issuance of a significant patent by the Japanese Patent Office for its ThermoStem® Program, which focuses on methodologies for deriving brown adipocytes from human brown adipose-derived stem cells. The patent underscores the potential of brown fat in improving metabolic processes, including calorie burning and glucose regulation. CEO Lance Alstodt highlighted the growing value of their intellectual property. The company is utilizing stem cell protocols for various therapies, including treatments for disc/spine diseases and obesity.
Summary not available.
BioRestorative Therapies (OTC: BRTX) announces its annual stockholders meeting on August 17, 2021, at 10 a.m. EDT. Key proposals for vote include the reincorporation from Delaware to Nevada and a reverse stock split. Majority approval is required for these changes. Stockholders of record as of June 24, 2021, are encouraged to vote online or attend in person. The company focuses on developing stem cell-based therapies, with lead product BRTX-100 targeting chronic lower back pain.
BioRestorative Therapies (OTC: BRTX) announced the filing of a registration statement on Form S-1 with the SEC for a proposed underwritten public offering of its securities. The offering's completion depends on the registration's effectiveness and market conditions. If successful, the net proceeds will fund clinical trials for BRTX-100, research and development for the metabolic ThermoStem Program, and general corporate expenses.